USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
CHANTEST, INC.
Address:
14656 NEO PKY
CLEVELAND, OH
Phone:
(216) 332-1665
URL:
N/A
EIN:
760505076
DUNS:
N/A
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $487,784.00 5
SBIR Phase II $1,764,756.00 2

Award List:

NOVEL SIMPLE SCREEN FOR POTASSIUM CHANNELS

Award Year / Program / Phase:
1998 / SBIR / Phase I
Award Amount:
$89,263.00
Agency:
HHS
Principal Investigator:
Lacerda, Antonio E
Abstract:
N/a

New drugs for treatment of atrial fibrillation

Award Year / Program / Phase:
2001 / SBIR / Phase I
Award Amount:
$99,924.00
Agency:
HHS
Principal Investigator:
Antonio E. Lacerda
Abstract:
Atrial fibrillation (AF) is the commonest cardiac arrhythmia and in its chronic form affects more than two million patients in the USA. AF is associated with cardiac and non-cardiac diseases. About 10% of cases have no obvious cause (lone AF). Stroke is the commonest complication with a 25% greater… More

New drugs for treatment of atrial fibrillation

Award Year / Program / Phase:
2003 / SBIR / Phase I
Award Amount:
$0.00
Agency:
HHS
Principal Investigator:
Antonio E. Lacerda
Abstract:
DESCRIPTION (provided by applicant): Atrial fibrillation (AF) is the most common cause of arrhythmias in the elderly; it has an incidence of more than 5 percent in people > 69 years of age. At present, there is no satisfactory treatment of this disease. The ChanTest Phase I SBIR was directed towards… More

New drugs for treatment of atrial fibrillation

Award Year / Program / Phase:
2003 / SBIR / Phase II
Award Amount:
$580,448.00
Agency:
HHS
Principal Investigator:
Antonio E. Lacerda
Abstract:
DESCRIPTION (provided by applicant): Atrial fibrillation (AF) is the most common cause of arrhythmias in the elderly; it has an incidence of more than 5 percent in people > 69 years of age. At present, there is no satisfactory treatment of this disease. The ChanTest Phase I SBIR was directed towards… More

Development of a Complete Proarrhythmic Safety Profile for Drugs

Award Year / Program / Phase:
2006 / SBIR / Phase I
Award Amount:
$149,322.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): ChanTest's goal is to commercialize a comprehensive non-clinical proarrhythmic profile that will screen compounds through a battery of models that span from the molecular (ion channels) to the multicellular (Purkinje fibers) to whole organ (Langendorff perfused… More

Optimizing the Action Potential of Stem Cell-derived Human Cardiomyocytes for Car

Award Year / Program / Phase:
2010 / SBIR / Phase I
Award Amount:
$149,275.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Stem Cell-derived Human Cardiomyocytes (SC-hCMs) offer great potential for improving the accuracy of pre-clinical cardiac safety screening. We have recently characterized a population of SC-hCMs that will be made commer cially available in 2010 by our… More

Optimizing the Action Potential of Stem Cell-derived Human Cardiomyocytes for Car

Award Year / Program / Phase:
2012 / SBIR / Phase II
Award Amount:
$1,184,308.00
Agency:
HHS
Principal Investigator:
Andrew H. Bruening-wright – 503-494-7732
Abstract:
DESCRIPTION (provided by applicant): Stem Cell-derived Human Cardiomyocytes (SC-hCMs) offer great potential for improving the accuracy of pre- clinical cardiac safety testing. We have characterized a population of SC-hCMs and have demonstrated that these cells show sensitive pharmacology that… More